Technical Analysis for TNXP - Tonix Pharmaceuticals Holding Corp.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.19 | -43.10% | -0.14 |
TNXP closed down 43.1 percent on Thursday, March 28, 2024, on 13.21 times normal volume. It ran into resistance at its 50 day moving average. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
50 DMA Resistance | Bearish | 0.00% | |
New 52 Week Closing Low | Bearish | 0.00% | |
Expansion Breakdown | Bearish Swing Setup | 0.00% | |
Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% | |
Wide Range Bar | Range Expansion | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 14 hours ago |
20 DMA Resistance | about 16 hours ago |
2x Volume Pace | about 16 hours ago |
1.5x Volume Pace | about 16 hours ago |
3x Volume Pace | about 16 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the development of pharmaceutical products for the disorders of central nervous system. The company's lead product candidate includes TNX-102 SL, a dose and formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of headaches; and TNX-301. The company was founded in 2007 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Sciences Drugs Pharmaceutical Products Disorders Post Traumatic Stress Disorder Headache Stage Specialty Pharmaceutical Fibromyalgia Seth Lederman
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Sciences Drugs Pharmaceutical Products Disorders Post Traumatic Stress Disorder Headache Stage Specialty Pharmaceutical Fibromyalgia Seth Lederman
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.0 |
52 Week Low | 0.167 |
Average Volume | 1,655,556 |
200-Day Moving Average | 0.73 |
50-Day Moving Average | 0.34 |
20-Day Moving Average | 0.34 |
10-Day Moving Average | 0.32 |
Average True Range | 0.04 |
RSI (14) | 21.88 |
ADX | 16.71 |
+DI | 9.17 |
-DI | 39.47 |
Chandelier Exit (Long, 3 ATRs) | 0.27 |
Chandelier Exit (Short, 3 ATRs) | 0.29 |
Upper Bollinger Bands | 0.42 |
Lower Bollinger Band | 0.26 |
Percent B (%b) | -0.47 |
BandWidth | 46.64 |
MACD Line | -0.02 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0113 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.45 | ||||
Resistance 3 (R3) | 0.47 | 0.41 | 0.41 | ||
Resistance 2 (R2) | 0.41 | 0.34 | 0.40 | 0.39 | |
Resistance 1 (R1) | 0.30 | 0.30 | 0.27 | 0.27 | 0.38 |
Pivot Point | 0.23 | 0.23 | 0.22 | 0.22 | 0.23 |
Support 1 (S1) | 0.12 | 0.16 | 0.09 | 0.10 | -0.01 |
Support 2 (S2) | 0.06 | 0.12 | 0.04 | -0.02 | |
Support 3 (S3) | -0.06 | 0.06 | -0.04 | ||
Support 4 (S4) | -0.08 |